NCT06878573Completed
Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema
Description of the Changes of Ocular Perfusion in Patients with Age-related Maculopathy or Diabetic Macula Edema After Intravitreal Aflibercept Injection Treatment
Source: ClinicalTrials.gov · Last updated 17 Mar 2025
Brief summary (registry, in English)
This prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept. Ocular perfusion will be measured by Laser Speckle Flowgraphy (LSFG). The parameter Mean Blur Rate (MBR) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. MBR will be measured at the optic nerve head (ONH). The devices software can analyze MBR in areas of major retinal vessels (MV) and in microperfusion areas (MT) separately. Measurements will be conducted on the day of the planned intravitreal injection and one and four weeks post-injection.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 36 (actual)
- First submitted
- 6 Mar 2025
- Start date
- 22 Nov 2023
- Primary completion date
- 29 Jun 2024
- Lead sponsor
- Augenabteilung Allgemeines Krankenhaus Linz
- Diseases
- Macular degeneration, Diabetic eye disease
- NCT number
- NCT06878573
What you commit to
- Study type: Observational
- Participants enrolled: 36
- From 22 Nov 2023 to the primary completion date, 29 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- ocular surgery (including intravitreal injection) during the 3 months preceding the study
Other illness
- any relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. glaucoma, optic nerve head drusen, tilted disc, etc.).
Other
- Ametropia \> 6 Dpt
Who the study is looking for
- age \> 50 years,
- patients scheduled for an intravitreal injections with Aflibercept for treatment of DME or AMD.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department for Ophthalmology Coordinator of this site? Confirm its status | Linz | Austria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.